Study of the Safety, Tolerability, Pharmacokinetics of VV147 Tablets in Chinese Healthy Participants.

1. Aged 18 to 45 years old, males or females;
2. Males weight no less than 50 kg, females weight no less than 45 kg, with body mass index of 19.0 to 26.0 kg/m² (inclusive of 19.0 and 26.0);
3. Female participants of childbearing potential must have a negative pregnancy test，all participants (including males) must agree not to plan a pregnancy or donate sperm/ova from 14 days prior to dosing until 3 months after the study ends, and must voluntarily adopt effective contraceptive measures;
4. Participants who are able to understand and follow the study protocol and instructions and volunteers who have voluntarily decided to participate in this study, and sign the informed consent form.

Exclusion Criteria:

1. Participants with hypersensitivity to preparation or any of the excipients, or allergies to two or more types of foods, drugs, or specific substances;
2. Participants with central nervous, cardiovascular, digestive, endocrine, respiratory, urinary, immune, or hematologic systems; or confirmed renal, hepatic, or metabolic abnormalities requiring medical intervention，or other conditions deemed by the investigator to make the subject unsuitable for the clinical trial (e.g., a history of malignant tumors);
3. Participants with a history of epileptic seizures;
4. Past or current neuropsychiatric disorders (e.g., depression, mania, schizophrenia), a family history of neuropsychiatric disorders, a history of suicidal behavior, or suicidal ideation or risk as assessed by the investigator using the Columbia-Suicide Severity Rating Scale (C-SSRS);
5. Participation in other clinical trials of drugs or medical devices within the 3 months prior to screening;
6. Participants who have donated blood or experienced blood loss of ≥400 mL within 3 months prior to screening, have a history of using blood products, or plan to donate blood during the trial or within 3 months after the last dose of the study drug;
7. Participants who have undergone major surgery or surgery likely to significantly affect the in vivo behavior of the study drug or safety assessments (e.g., gastrointestinal resection, cholecystectomy, or other surgeries affecting drug absorption or metabolism) within 3 months prior to screening, or who plan to undergo surgery during the study or within 2 weeks after the study ends;
8. Participants who have taken any prescription drugs, over-the-counter (OTC) medications, herbal medicines, or dietary supplements within 2 weeks prior to screening;
9. Participants who have received a vaccination within 14 days prior to screening, or plan to receive a vaccination within 1 week after the study ends;
10. Participants who test positive in a drug abuse screen, or have a history of drug abuse or illicit drug use within 1 year prior to screening;
11. Participants with alcohol addiction;(those who drink at least twice daily or consume more than 14 units of alcohol per week),or those who engage in binge drinking ,or those who test positive in a breath alcohol test, or those unable to abstain from alcohol or alcohol-containing products from the time of screening through the duration of the clinical trial;
12. Participants who smoked within 1 year prior to screening (consuming more than 10 cigarettes or an equivalent amount of tobacco daily), or unable to abstain from using tobacco products from screening through the clinical trial period;
13. Unable to tolerate venipuncture or having difficulty with blood sampling, or a history of needle phobia or fainting at the sight of blood;
14. Consumed excessive amounts (more than 5 cups; 1 cup ≈ 250 mL) of tea, coffee, or caffeine-containing foods or beverages daily within 3 months prior to screening, or unwilling to abstain from consuming tea, coffee, or caffeine-containing foods or beverages during the trial;
15. Unable to abstain from strenuous exercise during the trial;
16. Has special dietary requirements and cannot adhere to the standardized diet, or has difficulty swallowing tablets;
17. Tests positive for Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (Anti-HCV), *Treponema pallidum* antibody, or HIV antibody;
18. Clinically significant abnormalities in vital signs, physical examination, or laboratory tests;
19. Clinically significant abnormalities in chest X-ray (posteroanterior view);
20. Clinically significant abnormalities in abdominal ultrasound (liver, gallbladder, pancreas, spleen, kidneys);
21. Clinically significant abnormalities in 12-lead ECG, or corrected QT interval (QTcF) > 450 ms (calculated using Fridericia's formula);
22. Pregnant or lactating women;
23. Any other factors deemed by the investigator to make the participants who unsuitable for participation in the trial.